HDACi treatment might improve the outcome of autoimmune and autoinflammatory-like inflammatory bowel disease (IBD) or RA through the induction of FLS growth arrest, anti-angiogenic properties, or suppression of pro-inflammatory cytokines like IL-6 and TNF-α [59,60,61,62]. This evidence concerns the gene IL6 and inflammatory bowel disease.